Abstract 11499: Incremental Prognostic Significance of the Elevated Levels of Pentraxin 3 in Patients With Heart Failure With Normal Left Ventricular Ejection Fraction

Backgrounds: Pentraxin 3 (PTX3) is a novel inflammatory maker and produced by various cell types including vasculature and heart. We have shown that PTX3 is significantly elevated in patients with heart failure with normal left ventricular ejection fraction (HFNEF) and it is an independent inflammatory marker correlated with the presence of HFNEF. We investigate whether plasma levels of PTX3 could predict occurrence of future cardiovascular (CV) events in patients with HFNEF. Methods: We conducted a prospective cohort study of 360 HFNEF patients (age 70.5±9.9, male 55.5%) with measuring plasma inflammatory markers (PTX3, high-sensitivity C-reactive protein [hsCRP], tumor necrosis factor-α and interleukin-6) and B-type natriuretic peptide (BNP) and followed CV events, which were a composite of CV death, non-fatal myocardial infarction or ischemic stroke, unstable angina, hospitalization for HF, or coronary revascularization. Results: A total of 106 patients had a CV event. Kaplan-Meier analysis demonstrate...